18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer

Marafi, Fahad; Sasikumar, Arun; Alfeeli, Mahmoud; Fathallah, Wael

doi:10.1097/rlu.0000000000002821

Cited by 14 publications

(81 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tissue staining with three different anti-PSMA antibodies showed heterogeneous results, with one antibody negative for all three tumor cell lines (ab58779, Abcam), one positive in all three (NBP1-45057, Novus), and one split (NBP1-89822, Novus). PSMAspecific binding was confirmed by application of the PSMA-antagonist PMPA which effectively suppressed 68 Ga-PSMA and 18 F-DCFPyL binding. They found that activated microglia expression (CD11b) was low intratumorally and peritumorally but activated astrocyte expression (GFAP) was high peritumorally.…”

Section: Expression Of Psma In Tissue and Preclinical Modelsmentioning

confidence: 89%

“…They found that both PSMA-targeting tracers exhibited strong binding in the peritumoral area but moderate binding in the tumor core. In vivo animal PET imaging showed a higher tumor to background ratio (TBR) for 18 F-DCFPyL (TBR 6.28-7.92) than 68 Ga-PSMA (TBR 3.22-3.92). Tissue staining with three different anti-PSMA antibodies showed heterogeneous results, with one antibody negative for all three tumor cell lines (ab58779, Abcam), one positive in all three (NBP1-45057, Novus), and one split (NBP1-89822, Novus).…”

Section: Expression Of Psma In Tissue and Preclinical Modelsmentioning

confidence: 99%

“…They may have a lower resolution than other isotopes, due to a longer photon range and the energy within the isotope. 68 Ga-PSMA-11 (HBED-CC) benefits from a high affinity for PSMA-expressing tumors. It also shows rapid blood clearance and lower liver uptake, though it has uptake in salivary glands [29].…”

Section: Psma-targeting Pet Tracermentioning

confidence: 99%

“…It has a much higher binding affinity for PSMA than its predecessor, 18 F-DCFBC, which also suffered from high blood pool activity which limited detection of lymph nodes near blood vessels. 18 F-PSMA-1007 is structurally 68 Ga-PSMA-617 but potentially has a better resolution [31]. When there are low PSA levels, subcentimeter bone lesions, lymph node involvement, or hepatic involvement, 68 Ga-PSMA agents are superior to 18 F-choline (Table 2).…”

Section: Fluorine-taggedmentioning

confidence: 99%

See 3 more Smart Citations

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

et al. 2022

View full text Add to dashboard Cite

Introduction. Positron emission tomography (PET) imaging with prostate-specific membrane antigen- (PSMA-) binding tracers has been found incidentally to demonstrate uptake in CNS tumors. Following the encouraging findings of several such case reports, there is a growing interest in the potential application of PSMA-targeted PET imaging for diagnostics, theranostics, and monitoring of CNS tumors. This is a systematic literature review on PSMA-binding tracers in CNS tumors. Methods. A PubMed search was conducted, including preclinical and clinical reports. One hundred and twelve records were identified, and after screening, 56 were included in the final report. Results. Tissue studies demonstrated PSMA expression in tumor vascular endothelial cells, without expression in normal brain tissue, though the extent and intensity of staining varied by anti-PSMA antibody and methodology. Most included studies reported on gliomas, which showed strong PSMA ligand uptake and more favorable tumor to background ratios than other PET tracers. There are also case reports demonstrating PSMA ligand uptake in prostate cancer brain metastases, nonprostate cancer brain metastases, and meningiomas. We also review the properties of the various PSMA-binding radiotracers available. Therapeutic and theranostic applications of PSMA-binding tracers have been studied, including labeled alpha- and beta-ray emitting isotopes, as well as PSMA targeting in directing MRI-guided focused ultrasound. Conclusions. There is a potential application for PSMA-targeted PET in neuro-oncology as a combination of diagnostic and therapeutic use, as a theranostic modality for managing CNS tumors. Further research is needed regarding the mechanism(s) of PSMA expression in CNS tumors and its differential performance by tumor type.

show abstract

Section: Expression Of Psma In Tissue and Preclinical Modelsmentioning

confidence: 89%

Section: Expression Of Psma In Tissue and Preclinical Modelsmentioning

confidence: 99%

Section: Psma-targeting Pet Tracermentioning

confidence: 99%

Section: Fluorine-taggedmentioning

confidence: 99%

See 2 more Smart Citations

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Several other radiotracers have been used in clinical assessments of BM, such as sodium [ 18 F]fluoride (Na[ 18 F]F) to detect BM and study tumor responses after chemotherapy, 99 [ 18 F]-fluorocholine to detect BM and distinguish them from other brain tumors, 100 rubidium ( 82 Rb), 101 [ 68 Ga]Ga-PSMA-11, 102 and [ 18 F]-PSMA-1007 103 to detect BM, and [ 18 F]fluoromisonidazole ([ 18 F]FMISO) to study intra-tumoral hypoxia. 104 …”

Section: Positron Emission Tomography (Pet)mentioning

confidence: 99%

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis

Aasen

Espedal

Keunen

et al. 2021

Neuro-Oncology Advances

View full text Add to dashboard Cite

Brain metastasis (BM) is a major cause of cancer patient morbidity. Clinical magnetic resonance imaging (MRI) and positron emission tomography (PET) represent important resources to assess tumor progression and treatment responses.In preclinical research, anatomical MRI and to some extent functional MRI have frequently been used to assess tumor progression. In contrast, PET has only to a limited extent been used in animal BM research. A considerable culprit is that results from most preclinical studies have showed little impact on the implementation of new treatment strategies in the clinic. This emphasizes the need for the development of robust, high-quality preclinical imaging strategies with potential for clinical translation.This review focuses on advanced preclinical MRI and PET imaging methods for BM, describing their applications in the context of what has been done in the clinic. The strengths and shortcomings of each technology are presented, and recommendations for future directions in the development of the individual imaging modalities are suggested. Finally, we highlight recent developments in quantitative MRI and PET, the use of radiomics and multimodal imaging, and the need for a standardization of imaging technologies and protocols between preclinical centers.

show abstract

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Uijen¹,

Derks

Merkx³

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [177Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.

show abstract

18F-PSMA 1007 Uptake in Brain Metastases From Breast Cancer

Cited by 14 publications

References 12 publications

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

Contact Info

Product

Resources

About